{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:01:08Z","timestamp":1763755268540,"version":"3.45.0"},"reference-count":8,"publisher":"Oncology Nursing Society (ONS)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2017,4,1]]},"DOI":"10.1188\/17.cjon.154-156","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T15:21:23Z","timestamp":1497885683000},"page":"154-156","source":"Crossref","is-referenced-by-count":4,"title":["Hypophysitis: Nursing Management of Immune-Related Adverse Events"],"prefix":"10.1188","volume":"21","author":[{"given":"Adrienne","family":"Vazquez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2017,3,17]]},"reference":[{"key":"1","unstructured":"Bristol-Myers Squibb Company. (2017). Opdivo\u00ae (nivolumab) [Package insert]. Princeton, NJ: Author."},{"key":"2","doi-asserted-by":"crossref","unstructured":"Carra, T., Gaudy-Marqueste, C., Albarel, F., Monestier, S., Mallet, S., Brue, T., . . . Grob, J. (2012). Ipilimumab-induced hypophysitis in melanoma patients [Abstract 8568]. Journal of Clinical Oncology, 30.","DOI":"10.1200\/jco.2012.30.15_suppl.8568"},{"key":"3","unstructured":"Merck Sharp & Dohme Corp. (2016). Keytruda\u00ae (pembrolizumab) [Package insert]. Whitehouse Station, NJ: Author."},{"key":"4","unstructured":"Porter, R.S., Kaplan, J.L., & Beers, M.H. (Eds.). (2006). The Merck manual (18th ed.). Whitehouse Station, NJ: Merck Research Laboratories."},{"key":"5","doi-asserted-by":"crossref","unstructured":"Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., . . . Hodi, F.S. (2015). Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New England Journal of Medicine, 372, 2006\u20132017. doi:10.1056\/NEJMoa1414428","DOI":"10.1056\/NEJMoa1414428"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Torino, F., Barnabei, A., de Vecchis, L., Salvatori, R., & Corsello, S.M. (2012). Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: Challenges from a new cause of a rare disease. Oncologist, 17, 525\u2013535. doi:10.1634\/theoncologist.2011-0404","DOI":"10.1634\/theoncologist.2011-0404"},{"key":"7","unstructured":"Villadolid, J., & Amin, A. (2015). Immune checkpoint inhibitors in clinical practice: Update on management of immune-related toxicities. Translational Lung Cancer Research, 4, 560\u2013575. doi:10.3978\/j.issn.2218-6751.2015.06.06"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Vinken, P.J., Bruyn, G.W., & Klawans, H.L. (2014). Handbook of clinical neurology (Vol. 124, pp. 417\u2013422). Amsterdam: North-Holland.","DOI":"10.1016\/B978-0-444-59602-4.00029-0"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/21\/2-0\/hypophysitis-nursing-management-immune-related-adverse-events","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:09Z","timestamp":1763754729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/21\/2\/hypophysitis-nursing-management-immune-related-adverse-events"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,17]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4,1]]}},"URL":"https:\/\/doi.org\/10.1188\/17.cjon.154-156","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2017,3,17]]}}}